Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing erosive esophagitis:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome):** Starting dose is typically 40 mg orally or intravenously twice daily. Doses can be increased as needed. Doses up to 240 mg intravenously daily have been administered.
## Pediatric Dosing
Dosing in pediatric patients can be complex and depends on age, weight, and indication. Consult specific pediatric guidelines or prescribing information.
* **Erosive esophagitis (ages 5 to 16 years):** 40 mg orally once daily for up to 8 weeks.
* **GERD symptom management (ages 5 to 16 years):** 20 mg to 40 mg orally once daily for up to 8 weeks.
## Dose Adjustments
No dose adjustment is generally required for patients with hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, dizziness, and flatulence. Long-term PPI use is associated with increased risk of *Clostridium difficile*-associated diarrhea, bone fractures, hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** PPIs can decrease the absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors.
* **Methotrexate:** Concomitant use with PPIs may increase methotrexate levels and toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19, which may affect the metabolism of drugs such as clopidogrel.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremors, muscle cramps, seizures).
* Monitor for efficacy in acid suppression and symptom relief.
* Long-term use may warrant monitoring for bone mineral density and vitamin B12 levels.
## Clinical Pearls
* Administer oral pantoprazole at least 1 hour before a meal.
* Intravenous administration requires reconstitution and dilution; follow manufacturer instructions carefully.
* Consider the potential for drug interactions, especially with gastric pH-dependent drugs and those metabolized by CYP2C19.
* Discuss risks and benefits of long-term PPI therapy with patients.
***
This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always verify current prescribing information and consult with your healthcare provider.
